Cocrystal Pharma doses last patient in Phase 1b norovirus challenge trial of CDI-988
COCP•Phase 1b norovirus challenge trial reaches last patient
Cocrystal Pharma dosed the last participant in a Phase 1b human challenge trial of oral norovirus candidate CDI-988.
- No serious adverse events have been reported so far, supporting continued clinical development following earlier Phase 1 safety results.
- The study is testing CDI-988 for prevention and treatment, aiming to reduce illness from norovirus versus placebo.
- Preliminary efficacy results are expected in late 2026 or early 2027; no efficacy findings have been presented yet.
